Coy Heldermon

Procession to IND of a capsid mutated AAV8 codon optimized NAGLU vector for treatment of Sanfilippo Syndrome type B

Lipid metabolism in triple-negative breast cancer biology and therapy

Isoform-Selective Disulfide Isomerase Inhibitors for Overcoming Drug Resistance

A Phase 1/2, Single Dose, Dose Escalation Study of Intravenous AAV5-GLA (AMT-191) in Adult Males with Classic Fabry Disease

Novel Targeted Anticancer Agents from Marine Cyanobacteria

Procession to IND of a capsid mutated AAV8 codon optimized NAGLU vector for treatment of Sanfilippo Syndrome type B

Effects of TLR4 antagonism on brain and bone function in MPS IIIB

The Gastrointestinal Microbiota and Breast Cancer

Implementation and Evaluation of a Rare Disease Algorithm to Identify Persons at Risk of Gaucher Disease Using Data from Electronic Health Records (EHRs) in the United States

Effect of cisternal or intravenous AAVtcm8co-NAGLU on digestive function in the MPS IIIB mouse

HER1-3 and Death Receptor protein folding as therapeutic vulnerabilities

Reducing racial disparity in breast cancer survival with a novel synthetic-lethal strategy

Novel therapeutic development for breast cancer

Oncogenic signaling that promotes lipid synthesis and resistance to ferroptosis

Novel Breast Cancer Therapeutics Targeting a Unique Subset of Disulfide Isomerases

A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects with Fabry Disease

Development of first-in-class HDAC3-selective degraders for breast cancer therapy

Novel Mechanism of Action and Translational Potential of the HDAC Inhibitor SR-4370 for Treating Breast Cancer

Novel immunologic therapy of soft tissue sarcoma

Lipidnanoparticle vaccines targeting metastatic lung cancer from osteosarcoma

Task Order #7 - AAV-mediated therapy for MPS IIIB

Molecular mechanisms and pharmacologic targeting of lipogenesis in breast cancer####

Novel oral targeted breast carcinoma vaccine

A multi-center, open-label, uncontrolled, single-arm, extension study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease.

A Multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease